More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...

Both of these GLP-1 drugs were originally designed for diabetes, but their benefits keep expanding — KSTP health expert Dr.

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...